Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 2/20 | 0.44 |
| ▸ | EDNRA | P25101 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595880 | 1.00 | PTGS2 (0.46) | PTGS2AKR1C3AKR1C2HSD17B2ATM | |
| SCHEMBL1887800 | 0.83 | TAAR1 (0.46) | PTGS2AKR1C3AKR1C2ALDH1A1MMP2 | |
| SCHEMBL10051059 | 0.83 | CA1 (0.55) | ALDH1A1 | |
| SCHEMBL18640198 | 0.83 | HSD17B2 (0.43) | PTGS2HSD17B2ATMALDH1A1MAPK1 | |
| SCHEMBL23913703 | 0.81 | ALDH1A1 (0.48) | HSD17B2ATMALDH1A1MAPK1EDNRB | |
| SCHEMBL3679487 | 0.81 | LMNA (0.54) | HSD17B2ATMALDH1A1EDNRBEDNRA | |
| SCHEMBL31668877 | 0.81 | LMNA (0.54) | HSD17B2ATMALDH1A1EDNRBEDNRA | |
| SCHEMBL31391247 | 0.81 | LMNA (0.54) | HSD17B2ATMALDH1A1EDNRBEDNRA | |
| SCHEMBL3035464 | 0.79 | ATM (0.46) | HSD17B2ATMALDH1A1MAPK1EDNRB | |
| SCHEMBL99072 | 0.78 | PSIP1 (0.56) | HSD17B2ATMALDH1A1MAPK1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118763273-A | Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof | 青岛赛锂达储能产业技术研究院有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-115084655-A | Electrolyte, preparation method thereof and lithium metal battery containing electrolyte | 蜂巢能源科技(无锡)有限公司 | 2022-09-20 | — | — | CN | claimed |
| EP-4743453-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4685143-A1 | DOUBLE REGULATOR FOR MGLUR5 AND HDAC6 AND USE THEREOF | Vivozon,Inc. (KR) | 2026-01-28 | — | — | EP | disclosed |
| US-20250382279-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-18 | — | — | US | disclosed |
| EP-4654972-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2025-08-07 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| CN-1125221-A | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect | GRUENENTHAL GMBH (DE) | 1996-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | PTGS2 1147/4885AKR1C3 3612/4885AKR1C2 3734/4885 |
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | QDPR, MAOB, DRD2 | PTGS2 1402/4885AKR1C3 2434/4885AKR1C2 1600/4885 |
| US-20250382279-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | PTGS2 2860/4885AKR1C3 2177/4885AKR1C2 1476/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | PTGS2 4496/4885AKR1C3 2119/4885AKR1C2 2268/4885 |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | PTGS2 625/4885AKR1C3 329/4885AKR1C2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.